PARIS (Agefi-Dow Jones)–The biotechnology company Valneva announced on Wednesday that it has reached an amicable agreement with the British government following the latter’s termination of a contract for the supply of 100 million doses of its candidate- vaccine against Covid-19.
London had canceled this order in September, claiming that the French laboratory had failed in its obligations, which Valneva had disputed.
“The settlement agreement resolves certain points relating to the obligations of Valneva and [du gouvernement britannique] following the termination of the supply agreement and also clarifies others contained in the clinical trial agreement [du vaccin] in the UK, which remains in force,” Valneva said in a statement.
“The company retains certain obligations under the provisions of the supply contract that survive its termination,” she added.
-Francois Schott, Agefi-Dow Jones; 01 41 27 47 92; [email protected] ed: LBO
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
June 15, 2022 12:29 ET (16:29 GMT)